Source: Xconomy

Dyne: Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

Not long ago, having early data about how an experimental drug worked in humans was expected of biotechs considering IPOs. Dyne Therapeutics may not reach human testing until 2022, but, like many of its preclinical peers this year, the company is choosing to jump into public markets now while investor interest in the biotech sector [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Joshua Brumm's photo - President & CEO of Dyne Therapeutics

President & CEO

Joshua Brumm

CEO Approval Rating

90/100

Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more